Table 2.

Compliance with aspirin treatment according to pill counting in 243 evaluable patients with ET

Fully compliant (n =218)*Partially compliant (n = 21)†Noncompliant (n = 4)‡Global P
Sex    .23 
 Male 104 (47.7) 6 (28.6) 2 (50)  
 Female 114 (52.3) 15 (71.4) 2 (50)  
Age at enrollment, median (IQR), y 60 (51.3-67) 54 (45-66) 54 (43.3-64) .21 
TXB2 at visit 2, median (IQR), ng/mL 18.6 (8.9-42.9) 22.8 (13.6-37) 46.5 (24-107.8) .40 
Treatment, 100 mg    .60 
 Once daily 73 (33.5) 10 (47.6) 2 (50)  
 Twice daily 71 (32.6) 7 (33.3) 1 (25)  
 Thrice daily 74 (33.9) 4 (19.1) 1 (25)  
Fully compliant (n =218)*Partially compliant (n = 21)†Noncompliant (n = 4)‡Global P
Sex    .23 
 Male 104 (47.7) 6 (28.6) 2 (50)  
 Female 114 (52.3) 15 (71.4) 2 (50)  
Age at enrollment, median (IQR), y 60 (51.3-67) 54 (45-66) 54 (43.3-64) .21 
TXB2 at visit 2, median (IQR), ng/mL 18.6 (8.9-42.9) 22.8 (13.6-37) 46.5 (24-107.8) .40 
Treatment, 100 mg    .60 
 Once daily 73 (33.5) 10 (47.6) 2 (50)  
 Twice daily 71 (32.6) 7 (33.3) 1 (25)  
 Thrice daily 74 (33.9) 4 (19.1) 1 (25)  

Data are n (%), unless otherwise indicated. The P values were calculated using the Kruskal-Wallis test or χ2 test for continuous or discrete variables, respectively.

*

All 9 pills in the 3 days before visit 3.

†

Six to 8 pills in the 3 days before visit 3.

‡

No pill in the 3 days before visit 3.

View Large